NIH Reporter #5R01AI130092-08

Research Grant for Small Molecule Protease Inhibitors Targeting MERS-CoV and Pandemic Coronaviruses

This opportunity is a research grant from the National Institute of Allergy and Infectious Diseases (NIAID) in partnership with Kansas State University, focused on antiviral drug discovery for coronaviruses. - Government Buyer: - National Institute of Allergy and Infectious Diseases (NIAID) - Collaboration with Kansas State University - Products/Services Requested: - Research and development services to identify orally available small molecule protease inhibitors for MERS-CoV and other pandemic coronaviruses - Emphasis on preclinical candidate and backup compound identification - Evaluation of inhibitors against merbecovirus and sarbecovirus 3C-like protease - Unique/Notable Requirements: - Focus on antiviral drug discovery and preclinical candidate identification for coronaviruses - No specific OEMs or commercial products required; this is a research and development grant - Estimated contract value: $731,548 - Funding opportunity announcement: PA-20-185

Description

This is a research grant opportunity focused on developing orally available antivirals for MERS-CoV and evaluating inhibitors against merbecovirus and sarbecovirus 3C-like protease. The project aims to identify a preclinical candidate and backup compounds for MERS-CoV infection. The solicitation is issued by the National Institute of Allergy and Infectious Diseases (NIAID) and involves research and development work. The funding opportunity announcement is PA-20-185 with a CFDA code of 93.855.

View original listing